4.85
price down icon2.02%   -0.10
after-market Dopo l'orario di chiusura: 4.81 -0.04 -0.82%
loading

Candel Therapeutics Inc Borsa (CADL) Ultime notizie

pulisher
02:15 AM

Candel Therapeutics (CADL) Projected to Post Earnings on Thursday - MarketBeat

02:15 AM
pulisher
Mar 04, 2026

Candel Therapeutics, Inc. showcases linoserpaturev immunotherapy progress in recurrent glioblastoma case - Traders Union

Mar 04, 2026
pulisher
Mar 04, 2026

United StatesGoodwin Guides Candel Therapeutics On $100 Million Public Offering And $100 Millon Royalty Funding Agreement With RTW - Mondaq

Mar 04, 2026
pulisher
Mar 04, 2026

CADL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Mar 04, 2026
pulisher
Mar 02, 2026

Understanding the Setup: (CADL) and Scalable Risk - Stock Traders Daily

Mar 02, 2026
pulisher
Mar 02, 2026

New Candel Therapeutics hire gets 20,000 stock options at $5.25 - Stock Titan

Mar 02, 2026
pulisher
Mar 02, 2026

Candel Therapeutics CEO to present progress on immunotherapies at TD Cowen Health Care Conference - Traders Union

Mar 02, 2026
pulisher
Feb 28, 2026

CADL Stock News Today | Earnings, Events & Price Alerts - Intellectia AI

Feb 28, 2026
pulisher
Feb 27, 2026

Hedge Fund and Insider Trading News: David Tepper, Steve Cohen, Ray Dalio, Brevan Howard, Millennium Management, Citadel Investment Group, Candel Therapeutics Inc (CADL), Meta Platforms Inc (META), and More - Insider Monkey

Feb 27, 2026
pulisher
Feb 27, 2026

Candel Therapeutics Insider Bought Shares Worth $2,999,996, According to a Recent SEC Filing - marketscreener.com

Feb 27, 2026
pulisher
Feb 27, 2026

Paul Manning buys Candel Therapeutics (CADL) shares worth $3m - Investing.com

Feb 27, 2026
pulisher
Feb 26, 2026

Candel Therapeutics (NASDAQ:CADL) Director Paul Manning Purchases 550,458 Shares - MarketBeat

Feb 26, 2026
pulisher
Feb 26, 2026

Paul Manning buys Candel Therapeutics (CADL) shares worth $3m By Investing.com - Investing.com India

Feb 26, 2026
pulisher
Feb 26, 2026

Director Paul B. Manning adds 550,458 Candel (NASDAQ: CADL) shares via revocable trust - Stock Titan

Feb 26, 2026
pulisher
Feb 26, 2026

Candel Therapeutics, Inc. (CADL) Stock Analysis: Unveiling a 259% Potential Upside in Biotech - DirectorsTalk Interviews

Feb 26, 2026
pulisher
Feb 25, 2026

Candel Therapeutics, Inc. unveils science behind CAN-2409 driving durable tumor immune response - Traders Union

Feb 25, 2026
pulisher
Feb 24, 2026

Candel Therapeutics CEO to present at TD Cowen health care conference on March 3 - Proactive financial news

Feb 24, 2026
pulisher
Feb 24, 2026

Candel Therapeutics to Present at TD Cowen's 46th Annual Health Care Conference in Boston - Bitget

Feb 24, 2026
pulisher
Feb 24, 2026

Candel Therapeutics to Present at TD Cowen’s 46th Annual Health Care Conference in Boston - The Manila Times

Feb 24, 2026
pulisher
Feb 24, 2026

Candel Therapeutics CEO to speak at TD Cowen Boston conference - Stock Titan

Feb 24, 2026
pulisher
Feb 23, 2026

Candel Therapeutics Announces Equity Offering to Fund CAN-2409 - TipRanks

Feb 23, 2026
pulisher
Feb 23, 2026

Candel Therapeutics Prices 18.35M-Share Offering at $5.45, Expects ~$93.5M Net Proceeds - TradingView

Feb 23, 2026
pulisher
Feb 23, 2026

Candel Therapeutics (NASDAQ: CADL) prices $100M common stock sale - Stock Titan

Feb 23, 2026
pulisher
Feb 22, 2026

CADLCandel Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan

Feb 22, 2026
pulisher
Feb 22, 2026

Candel Therapeutics Faces Strategic Financial Moves Amidst Stock Offering - timothysykes.com

Feb 22, 2026
pulisher
Feb 21, 2026

Candel Therapeutics Prices $100M Public Offering - Intellectia AI

Feb 21, 2026
pulisher
Feb 21, 2026

Candel Therapeutics Faces Market Reaction Post-Secondary Offering - StocksToTrade

Feb 21, 2026
pulisher
Feb 21, 2026

Candel Therapeutics’ Stock Offering Sees Market Reaction - timothysykes.com

Feb 21, 2026
pulisher
Feb 21, 2026

Candel Therapeutics Prices $100 Million Share Offering - Intellectia AI

Feb 21, 2026
pulisher
Feb 21, 2026

Candel Therapeutics Faces Mixed Sentiments After Secondary Offering Announcement - StocksToTrade

Feb 21, 2026
pulisher
Feb 21, 2026

Candel Therapeutics, Inc. (NASDAQ:CADL) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Feb 21, 2026
pulisher
Feb 20, 2026

Candel Therapeutics files for offering of 18.3 mln shares of common stock - marketscreener.com

Feb 20, 2026
pulisher
Feb 20, 2026

Candel Therapeutics Files For Offering Of 18.3 Mln Shares Of Common Stock - TradingView

Feb 20, 2026
pulisher
Feb 20, 2026

Should I hold or sell Candel Therapeutics Inc. nowJuly 2025 Action & Risk Controlled Swing Alerts - mfd.ru

Feb 20, 2026
pulisher
Feb 20, 2026

Latham & Watkins Advises RTW Investments on US$100 Million Royalty Funding Agreement With Candel Therapeutics - Latham & Watkins LLP

Feb 20, 2026
pulisher
Feb 20, 2026

Key facts: Candel Therapeutics secures $100M funding; plans drug launches - TradingView

Feb 20, 2026
pulisher
Feb 20, 2026

Small cap wrap: EnWave, Nextech3D.ai, Candel Therapeutics, EDM Resources… - Proactive financial news

Feb 20, 2026
pulisher
Feb 20, 2026

Candel Therapeutics Initiates $100M Stock Offering Amid Market Fluctuations - StocksToTrade

Feb 20, 2026
pulisher
Feb 20, 2026

12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga

Feb 20, 2026
pulisher
Feb 20, 2026

Stock market today: Dow Jones, S&P 500 futures rise ahead of Q4 GDP numbers—Grail, Candel Therapeutics, Copart in focus - MSN

Feb 20, 2026
pulisher
Feb 20, 2026

Candel Therapeutics stock falls on $100 million offering pricing By Investing.com - Investing.com Canada

Feb 20, 2026
pulisher
Feb 20, 2026

Candel Therapeutics stock falls on $100 million offering pricing - Investing.com

Feb 20, 2026
pulisher
Feb 20, 2026

Stock Market Today: Dow Jones, S&P 500 Futures Slip After Weaker-Than-Expected GDP Report—Grail, Candel Therapeutics, Copart In Focus (UPDATED) - Benzinga

Feb 20, 2026
pulisher
Feb 20, 2026

Stock Market Today: Dow Jones, S&P 500 Futures Slip After Weaker-Than-Expected GDP Report—Grail, Candel Therapeutics, Copart In Focus (UPDATED) - Benzinga

Feb 20, 2026
pulisher
Feb 20, 2026

Candel Therapeutics prices $100M public offering - Proactive financial news

Feb 20, 2026
pulisher
Feb 20, 2026

Akamai, Grail, Candel Therapeutics - TradingView

Feb 20, 2026
pulisher
Feb 20, 2026

12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga

Feb 20, 2026
pulisher
Feb 20, 2026

Why Is Candel Therapeutics Stock Falling Friday? - Bitget

Feb 20, 2026
pulisher
Feb 20, 2026

Stock Market Today: Dow Jones, S&P 500 Futures Rise Ahead Of Q4 GDP Numbers-Grail, Candel Therapeutics, Copart In Focus - Bitget

Feb 20, 2026
pulisher
Feb 20, 2026

Candel Therapeutics Prices $100 Million Public Offering - marketscreener.com

Feb 20, 2026
pulisher
Feb 20, 2026

Cancer biotech Candel prices $100M sale to back prostate launch prep, lung trial - Stock Titan

Feb 20, 2026
pulisher
Feb 20, 2026

Candel Therapeutics, Inc. (CADL) Stock Analysis: Biotech's Potential 218% Upside Sparks Investor Interest - DirectorsTalk Interviews

Feb 20, 2026
pulisher
Feb 20, 2026

Candel Therapeutics prices $100M public offering at $5.45 per share - MSN

Feb 20, 2026
pulisher
Feb 19, 2026

The Technical Signals Behind (CADL) That Institutions Follow - Stock Traders Daily

Feb 19, 2026
pulisher
Feb 19, 2026

Candel Therapeutics announces pricing of public offering of 18,348,624 shares at $5.45 each - marketscreener.com

Feb 19, 2026
pulisher
Feb 19, 2026

Candel Therapeutics Announces Pricing Of Public Offering Of 18,348,624 Shares At $5.45 Each - TradingView

Feb 19, 2026
pulisher
Feb 19, 2026

Candel Therapeutics Announces Pricing of Public Offering - GlobeNewswire

Feb 19, 2026
pulisher
Feb 19, 2026

Candel Launches $100 Million Public Offering - Intellectia AI

Feb 19, 2026
$45.68
price down icon 3.69%
$53.83
price down icon 6.87%
$29.72
price up icon 0.68%
$101.95
price down icon 1.78%
$143.57
price down icon 4.21%
biotechnology ONC
$292.94
price down icon 2.03%
Capitalizzazione:     |  Volume (24 ore):